

#### US005399346A

## United States Patent [19]

### Anderson et al.

[11] Patent Number:

5,399,346

[45] Date of Patent:

Mar. 21, 1995

[54] GENE THERAPY

[75] Inventors: W. French Anderson, Bethesda; R.

Michael Blaese, Rockville; Steven A.

Rosenberg, Bethesda, all of Md.

[73] Assignee: The United States of America as

represented by the Department of Health and Human Services,

Washington, D.C.

[21] Appl. No.: 220,175

[22] Filed: Mar. 30, 1994

#### Related U.S. Application Data

[63] Continuation of Ser. No. 904,662, Sep. 8, 1992, abandoned, which is a continuation-in-part of Ser. No. 868,794, Apr. 15, 1992, abandoned, which is a continuation-in-part of Ser. No. 807,446, Dec. 13, 1991, abandoned, which is a continuation-in-part of Ser. No. 365,567, Jun. 14, 1989, abandoned.

 [56]

# References Cited PUBLICATIONS

Siegel, Los Angeles Times, Dec. 14, 1987, "Desire to be First Colors Gene Studies" pp. 1,22-25. Buden, The Scientist, Jan. 23, 1989, "Controversy Surrounds Gene Therapy Effort", pp. 1-3. Siegel, Los Angeles Times, Dec. 13, 1987, "Egos, Prizes on the Line for Scientists", pp. 1, 37-40. Anderson, John W., The Nation, Apr. 10, 1989, "Scrambling for Biotech Bucks", pp. 476-478. Selden, N. Eng. J. Med., vol. 318, No. 20, pp. 1337-1338.

Thompson, Time, Jun. 7, 1993 "The First Kids With New Gene" pp. 50-53.

Primary Examiner—Jacqueline Stone
Attorney, Agent, or Firm—Elliot M. Olstein; Raymond J.
Lillie

#### [57] ABSTRACT

Primary human cells which are genetically engineered with DNA (RNA) encoding a marker or therapeutic which is expressed to be expressed in vivo. Such engineered cells may be used in gene therapy.

14 Claims, 6 Drawing Sheets